Verici Dx Plc (63V) Price & Analysis
63V Stock Chart & Stats
- Day’s Range
- EUR 0.02 - EUR 0.03
- 52-Week Range
- EUR 0.01 - EUR 0.05
- Previous Close
- EUR 0.02
- Volume
- 0
- Average Volume (3M)
- 370
- Market Cap
- EUR 18.32M
- Enterprise Value
- EUR 4.58M
- Total Cash (Recent Filing)
- EUR 2.41M
- Total Debt (Recent Filing)
- EUR 776.01K
- Price to Earnings (P/E)
- ―
- Beta
- -2.41
- Next Earnings
- Jul 05, 2027
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Rapid revenue expansion indicates increasing commercial adoption of Verici Dx’s transplant-focused diagnostic products. If sustained, the larger revenue base can improve operating leverage, support broader clinical uptake, and create a stronger foundation for future profitability.
Gross Profit Growth
Positive and increasing gross profit demonstrates that the company’s products are generating economic value above direct costs. Continued gross-profit growth could provide a durable pathway toward improved margins as commercial scale expands, even though overall profitability remains negative.
Low Leverage
Declining debt and positive equity give Verici Dx a comparatively less leveraged financial structure. This reduces balance-sheet interest pressure and preserves more flexibility for investment in diagnostic commercialization, although ongoing losses still weaken that advantage over time.
Bears Say
Persistent Net Losses
Sizable and persistent net losses show that revenue growth has not yet translated into a sustainable earnings model. The widening 2025 loss increases the distance to profitability and may constrain internal reinvestment, making future financial progress dependent on stronger operating leverage.
Negative Cash Generation
Continued negative operating and free cash flow means the business is consuming cash to operate and grow rather than funding itself internally. The worsening 2025 burn increases reliance on external financing if the pattern persists, raising execution and funding pressure over the medium term.
Shrinking Asset Base
A substantially smaller asset base alongside negative returns on equity signals that accumulated resources are not yet producing attractive financial returns. If losses continue, further balance-sheet erosion or additional funding could dilute existing holders and limit strategic flexibility.
Verici Dx Plc News
63V FAQ
What was Verici Dx Plc’s price range in the past 12 months?
What is Verici Dx Plc’s market cap?
When is Verici Dx Plc’s upcoming earnings report date?
How were Verici Dx Plc’s earnings last quarter?
Is Verici Dx Plc overvalued?
Does Verici Dx Plc pay dividends?
What is Verici Dx Plc’s EPS estimate?
How many shares outstanding does Verici Dx Plc have?
What happened to Verici Dx Plc’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Verici Dx Plc?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Verici Dx Plc
Verici Dx plc is an immuno-diagnostics company primarily focused on the kidney transplantation sector. The firm specializes in creating both predictive and diagnostic assays for patients who have undergone kidney transplants. Its development pipeline features Clarava, a pre-transplant tool designed to forecast the likelihood of early acute rejection; Tuteva, a post-transplant assessment focusing on acute cellular rejection; and Protega, an innovative liquid biopsy aiming to predict the risk of fibrosis and eventual graft failure. Established in 2020, Verici Dx plc maintains its headquarters in Penarth, United Kingdom.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Sara jane Barrington
- Employees
- 18
- Website
- www.vericidx.com
- Address
- Avon House, Cardiff, TN, CF64 2EZ, GB
Verici Dx Plc (63V) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 4 | 4 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 9 | 0 | 1 |